Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' shares declined and the company narrowed its future guidance, signaling lower expectations ahead. CEO Henrik Andersen described the quarter as strong and busy despite the challenges, thanking stakeholders for their support.
Vestas Wind Systems' Q3 2026 earnings missed estimates, with EPS of $0.13 and revenue of $6.34 billion. For readers following Industrials-sector stocks, here is Pluang's market snapshot as of Nov 12, 2026 04:22 WIB: out of 135 priced US Industrials stocks, 105 rose and 29 fell. Notable movers include Powell Industries (POWL) up 5.69% at USD 146.07 with a typical hold time of 17 days, Rocket Lab USA Inc (RKLB) up 5.68% at USD 66.27 with 96% sell order activity, and Comfort Systems USA Inc (FIX) up 5.19% at USD 1,163.38 with 100% sell order activity and a typical hold time of 43 days.
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
Tennessee American Water has applied an additional $13.07 credit to customer accounts, bringing total PFAS settlement refunds to over $84 per customer. This credit follows approval from the Tennessee Public Utility Commission, allowing the company to...
PepGen Inc. stock surged over 100% following positive Phase 2 top-line results for its DM1 treatment PGN-EDODM1, which showed a 46.5% mean splicing correction and functional improvements with good safety at 10 mg/kg over four doses. Despite these pro...
